OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 5.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,330 shares of the biopharmaceutical company’s stock after buying an additional 2,243 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.08% of Agios Pharmaceuticals worth $1,424,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Jefferies Financial Group Inc. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth approximately $49,290,000. Adage Capital Partners GP L.L.C. bought a new position in Agios Pharmaceuticals during the fourth quarter valued at $9,957,000. Deutsche Bank AG increased its position in Agios Pharmaceuticals by 39.7% during the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company’s stock valued at $30,732,000 after acquiring an additional 265,637 shares during the last quarter. Casdin Capital LLC bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth about $8,215,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth about $8,151,000.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the company’s stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the transaction, the director now owns 149,220 shares of the company’s stock, valued at $3,864,798. This represents a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 4.30% of the stock is currently owned by corporate insiders.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $28.74 on Wednesday. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of 2.53 and a beta of 0.77. The company has a 50 day moving average price of $29.03 and a 200-day moving average price of $37.00. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. The company had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million. On average, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on AGIO shares. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price target on the stock. Finally, Scotiabank decreased their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating for the company in a research report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $56.00.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.